NCT06057610View on ClinicalTrials.gov

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

864

Participants

Timeline

Start Date

October 16, 2023

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2032

Conditions
HER2-PositiveRecurrent or Metastatic Breast Cancer
Interventions
DRUG

SHR-A1811 Injection

SHR-A1811 Injection

DRUG

SHR-A1811 Injection ； Pertuzumab Injection

SHR-A1811 Injection ； Pertuzumab Injection

DRUG

Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection

Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection

Trial Locations (1)

210029

RECRUITING

The First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY